<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782089</url>
  </required_header>
  <id_info>
    <org_study_id>ES-SCLC-2nd-IIT-SHR3162-APA</org_study_id>
    <nct_id>NCT04782089</nct_id>
  </id_info>
  <brief_title>Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open, Single-center Study of PD-1 Antibody and PARP Inhibitor as Consolidation Treatment for Patients With Extensive Stage Small Cell Lung Cancer Who Have Not Progressed After First-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation&#xD;
      Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed&#xD;
      after first-line treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess the efficacy of Camrelizumab and Fluzoparib combination therapy in terms of PFS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors</intervention_name>
    <description>Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable</description>
    <arm_group_label>Camrelizumab+Fluzoparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All subjects were required to sign the informed consent before starting the study;&#xD;
&#xD;
          2. Histologically documented Extensive stage small cell lung cancer；&#xD;
&#xD;
          3. ECOG PS 0~1 ；&#xD;
&#xD;
          4. 18-75 years；&#xD;
&#xD;
          5. According to recist1.1, CR or PR was achieved after 4-6 cycles of first-line etoposide&#xD;
             and platinum chemotherapy;&#xD;
&#xD;
          6. .Life expectancy ≥ 3 months；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrence or distant metastasis of localized small cell lung cancer after&#xD;
             chemotherapy or concurrent chemoradiotherapy；&#xD;
&#xD;
          2. Active infection including tuberculosis, HIV, hepatitis B and C；&#xD;
&#xD;
          3. Interstitial pneumonia (ILD), drug-induced pneumonia, radiation-induced pneumonia&#xD;
             requiring steroid therapy or active pneumonia with clinical symptoms, or other&#xD;
             moderate to severe lung diseases that seriously affect lung function;&#xD;
&#xD;
          4. Severe infection existed, including but not limited to infection complications,&#xD;
             bacteremia, severe pneumonia, etc;&#xD;
&#xD;
          5. Symptomatic brain metastasis and cancerous meningitis;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jisheng Li, PhD</last_name>
    <phone>0531-82169841</phone>
    <email>lijisheng@sdu.edu.cn</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

